- The Frankfurt Higher Regional Court upheld an ICC arbitral award in favor of AOP Health against PharmaEssentia, confirming the Taiwanese company's liability for damages in their BESREMi dispute. - The ruling ensures continued access to BESREMi (ropeginterferon alfa-2b) for approximately 12,600 polycythemia vera patients across AOP Health's European, CIS, and Middle Eastern territories. - BESREMi represents the first interferon approved specifically for polycythemia vera treatment and is described as the most extensively studied interferon in clinical trials for this rare blood cancer indication.

Apr 24, 2026

返回机构列表

AOP Orphan Pharmaceuticals GmbH

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（12）

Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS

Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 years with pulmonary arterial hypertension (PAH)

A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients

Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in PAH group I patients – TripleTRE

Study the effect of Landiolol on elevated heart rate by septic shock patients

Study the effect of Landiolol on elevated heart rate by septic shock patients

Study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in children.

药物批准

按机构分类的批准

近期批准

资讯

Frankfurt Court Upholds Arbitral Award Securing BESREMi Access for Polycythemia Vera Patients